Hemorrhagic shock (HS) and its sequelae of multiorgan dysfunction (MOD) and sepsis are the major leading cause of death after trauma. [1] Fluid, blood and its component, and stopping of bleeders have been the cornerstone of management since many decades.Cytokine storm dysregulates balance of pro-inflammatory and anti-inflammatory cytokines, which leads to clinically fatal outcome. [2] The role of bone marrow (BM) in trauma hemorrhagic shock (T/HS) has been ill-understood. BM dysfunction in T/HS leads to persistent anemia with increased susceptibility to infection and sepsis, mainly due to dyserythropoiesis and myelopoesis.BM dysfunction is a multifactorial process. Excessive pro-inflammatory cytokine milieu and elevated levels of circulating catecholamines change the behavior BM microenvironment in a T/HS. [3, 4] Survival and death machinery of hematopoietic stem and progenitor cells (HSPCs) is controlled by a complex interplay between intrinsic signals and stimuli from the surrounding BM microenvironment, inducing a dynamically balanced network of pro-survival and anti-survival influences. Alteration of this balance can lead to hematopoietic disorders, such as myeloproliferative disorders and BM dysfunction. [5] Human and animal model have shown that erythropoietin (EPO) acts as an anti-apoptotic, neuroprotective, anti-inflammatory, angiogenesis and stabilization of neurovascular function, and reduces oxidative stress by stimulating cell survival pathway (PI3k/Akt pathway). Treatment of rats with EPO for 3 days prior to induction of T/HS significantly attenuated renal (glomerular) dysfunction, liver and neuromuscular injury compared with pretreatment with vehicle. [6, 7] In humans, EPO (4,000 IU) injection into the site of tibiofibular fractures may possibly accelerate healing. [8] EPO receptor are found onearly burst forming unit-erythroid (BFU-E), as well as late erythroid progenitor cells (colony forming unit-erythroid (CFU-E), the first cells recognizable as committed to erythroid differentiation and nonhematopoietic tissue including central nervous system, endothelium, cardiac myocytes, kidney, and some solid cancer line. [7, 8] Livingston et al., studied behavior of peripheral and BM hematopoietic progenitor cell growth (HPCs) at various time intervals. Suppressed HPCs'growths were observed without reactivation. [3] The author feels that in-vitro BM function may be reactivated with EPO and growth factors. Synergistic or additive effect of growth factors (EPO, interleukin-3 (IL-3), and granulocyte-macrophage colony-stimulating factor (GM-CSF) on HPCs' growth in T/HS can be studied.It may provide insight to the effect of EPO with or without growth factors (IL3 and GM-CSF) on duration of recovery time of suppressed hematopoietic progenitor cell lines. This may provide the hypothesis in future human trial on use of growth factors in T/HS.
